A Phase Ib Study of Sapacitabine and Olaparib in Patients With BRCA1/2-Mutated (BRCA1/2m) Metastatic Breast Cancer
Demographics (3)
- AGE_AT_MET_DIAGNOSIS - Age at met diagnosis (years) (phv00570794.v1.p1)
- AGE_AT_PRIMARY_DX - Age at primary dx (years) (phv00570793.v1.p1)
- SEX - Biological sex (phv00570787.v1.p1)
Disease Events (1)
- GERMLINE_BRCA_MUTATION - Germline BRCA Mutation (phv00570797.v1.p1)
Race and Ethnicity (2)
- ETHNICITY - Self-reported race (phv00570792.v1.p1)
- RACE - Self-reported race (phv00570791.v1.p1)
Other (17)
- ANALYTE_TYPE - Analyte Type (phv00570804.v1.p1)
- BEST_OVERALL_RESPONSE - Best overall response (phv00570799.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00570803.v1.p1)
- COLLECTION_DAY - Collection day, denoted as the nth day since to the first day of the first year of the study. (phv00570806.v1.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body (phv00570786.v1.p1)
- DURATION_OF_RESPONSE - Duration of response (months) (phv00570800.v1.p1)
- IS_TUMOR - Tumor status (phv00570805.v1.p1)
- PRIOR_LINES_OF_TX - Prior lines of tx (phv00570798.v1.p1)
- REASON_FOR_STOPPING_TX - Reason for stopping tx (phv00570801.v1.p1)
- SAMPLE_ID - Sample ID (phv00570802.v1.p1)
- SAMPLE_ID - Sample ID (phv00570789.v1.p1)
- SUBJECT_ID - Subject ID (phv00570790.v1.p1)
- SUBJECT_ID - Subject ID (phv00570785.v1.p1)
- SUBJECT_ID - Subject ID (phv00570788.v1.p1)
- SUBTYPE_AT_MET_DIAGNOSIS - Subtype at met diagnosis (phv00570796.v1.p1)
- SUBTYPE_AT_PRIMARY_DIAGNOSIS - Subtype at primary diagnosis (phv00570795.v1.p1)
- VISIT - Visit; C stands for Cycle and D stands for Day in C1D1, C3D1, C5D1, etc., and EOT=end of treatment (phv00570807.v1.p1)